NCT04930900已完成1 期
A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration
研究概览
简要总结
This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on the clinical judgement and the positive infectious cause of URTI to be confirmed by Respiratory Pathogens Panel.
- •Has body weight more than 55 kg for male and 50 kg for female and body mass index between 18 and 32 kg/m2, inclusive.
- •Has no declared medical history of hypertension and cardiovascular disease in the last 10 years.
- •At screening, has stable vital signs in the following ranges (after 5 minutes of rest):
- •SBP ≥90 and ≤140 mmHg
- •DBP ≥50 and ≤90 mmHg
- •HR ≥45 and ≤100 beats per minute (bpm)
- •Is a nonsmoker within the previous 2 months (calculated from first dosing) and does not use tobacco-containing products.
排除标准
- •Has a stated history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Has current or past history of clinically significant asthma or angioedema.
- •Has prior nasal fractures, severe nasal injuries or history of nasal disorders that could interfere with nasal spray administration.
- •Has any clinically significant medical condition or physical exam (PE) finding as deemed inappropriate by the Investigator.
- •Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal ECG.
- •Subject reports they have had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening.
- •Subject reports they have donated blood including platelets or plasma only or had an acute loss of blood (>50 mL) during the 30 days before study drug administration or intends to donate blood or blood products within 30 days after the completion of the study.
- •Has a history (within 12 months before screening) of drug use, or has a positive test for drugs of abuse at screening or upon admittance to the study center, or has a stated history of alcohol abuse.
- •Has been on an abnormal diet during the four (4) weeks from Day
- •Has participated in a clinical trial within 30 days prior to the first dose of study drug.
- •Has had treatment with any adrenaline or noradrenaline containing products within 7 days of Day
- •Has inadequate or difficult venous access that may jeopardize the quality or timing of the PK samples.
研究组 & 干预措施
ARS-1 with URTI
Experimental
ARS-1 with URTI
干预措施: ARS-1 with URTI (Drug)
ARS-1 without URTI
Experimental
ARS-1 without URTI
干预措施: ARS-1 without URTI (Drug)
结局指标
主要结局
To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration
时间窗: Day -1 to Day 30
Blood samples will be collected to measure plasma concentrations of adrenaline
To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration
时间窗: Day -1 to Day 30
Blood samples will be collected to measure plasma concentrations of adrenaline
To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration
时间窗: Day -1 to Day 30
Blood samples will be collected to measure plasma concentrations of adrenaline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule FormulationHealthy VolunteerNCT02136524Genentech, Inc.28
终止
1 期
Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus SubjectsDiabetes MellitusNCT01755442Amgen5
已完成
1 期
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to SmokeTobacco Use DisorderTobacco DependenceSmokingNCT01428310Rock Creek Pharmaceuticals, Inc.109
已完成
1 期
Bioavailability of Levoketoconazole and Ketoconazole TabletsHealthyNCT04212000Cortendo AB34
已完成
1 期
Levoketoconazole Food Effect Study in Healthy SubjectsHealthy SubjectsNCT03768388Cortendo AB22